Eledon Pharmaceuticals, Inc. (ELDN) Q4 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to the Elladon Pharmaceuticals fourth quarter and full year 2022 financial results conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the forum presentation. As a reminder, this conference is being recorded today, March 30th, 2023. At this time, I would now like to turn the conference call over to Paul Little, Chief Financial Officer of Elladon. Please go ahead, sir. Good afternoon, everyone, and thank you for joining Elladon's fourth quarter and full year 2022 operating and financial results conference call. I'm joined on today's call by David Alexander Groh, Chief Executive Officer, and Steve Perrin, our President and Chief Scientific Officer. Jeff Borenstein, our Chief Medical Officer, is not present today as he is traveling to the World Congress of Nephrology. Earlier today, Elladon issued a press release announcing financial results for the fourth quarter and full year ended December 31st, 2022. You may access the release under the investors tab on our company's website at elladon.com. I would like to remind everyone that statements made during this conference call relating to Elladon's expected future performance, future business prospects or future events or plans may include forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All such forward-looking statements are intended to be subject to the safe harbor protection provided by the Reform Act. Actual outcomes and results could differ materially from these forecasts due to the impact of many factors beyond the control of ELEDON. ELEDON expressly disclaims any duty to provide updates to its forward-looking statements, whether as a result of new information, future events, or oth...